Non-Invasive Prenatal Testing

New generation NIPT for safe pregnancies


With VERACITY and VERAgene, you have the option of taking a highly accurate (>99%) and safe non-invasive prenatal test (NIPT) to check for genetic conditions of the fetus before birth with no risk for miscarriage. In both NIPTs, cell-free DNA from the mother’s blood is analyzed to detect potential changes in the genome including aneuploidies and microdeletions. Additionally, VERAgene tests for single gene (monogenic) disorders in the biological parents. Both tests are recommended for any pregnant women, independent of age and risk category and can be done from 10th week of pregnancy. Choose VERACITY to detect the most common fetal aneuploidies and microdeletions which occur more frequent with advanced maternal age. Choose VERAgene if you additionally want to simultaneously screen for other microdeletions and monogenic diseases that do not have any maternal age-associated risk and can have a significant impact on life quality. The outcome of the test can help parents take informed decisions about possible treatments and clinical management.


Detection of the most common fetal aneuploidies and microdeletions (all included in VERAgene as well) which occur more frequent with advanced maternal age. VERACITY has been validated by several clinical studies for single and twin pregnancies, and can also be used in pregnancies conceived through in-vitro fertilization (IVF).

Learn more


Simultaneous screen for aneuploidies (included in VERACITY), microdeletions and monogenic diseases provides a comprehensive solution to prospective parents using a single test. Genetic diseases screened in VERAgene are associated with significant impact on life quality.

Learn more

Rhesus factor test

With non-invasive fetal Rhesus factor (RhD) determination, RhD negative pregnant women can have their blood tested to determine the RhD of their unborn child.